MindBio Therapeutics (CSE:MBIO) announces the successful completion of its Phase 1 and 2a clinical trials on depression treatment.
Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Maroc - PHARMABIZ.COM - A la Une - 05/Jul 00:00
Calliditas' partner Viatris Pharma initiates phase III clinical trial with Nefecon in Japan
Calliditas Therapeutics AB (Calliditas) announces that its partner Viatris Pharmaceutical Japan G.K. (Viatris) has initiated a phase III clinical trial in Japan with Nefecon, named VR─205 in the Japanese market, in
Articles similaires
Key paediatric milestone reached in Dimerix’s kidney-disease drug trial
stockhead.com.au - 03:41
Clinical-stage biotech Dimerix has achieved a key milestone with the first paediatric site opening for its ACTION3 Phase 3 clinical ...
Key paediatric milestone reached in Dimerix’s kidney-disease drug trial
stockhead.com.au - 03:41
Clinical-stage biotech Dimerix has achieved a key milestone with the first paediatric site opening for its ACTION3 Phase 3 clinical ...
Crestone Announces Positive Data From Phase 2 Clinical Trial of CRS3123 for C. Difficile Infections (CDI)
drugs.com - 05/Sep 05:09
BOULDER, Colo.--(BUSINESS WIRE)-- September 05, 2024 -- Crestone, Inc. (“Crestone”) today announced positive topline results from the Phase 2...
Crestone Announces Positive Data From Phase 2 Clinical Trial of CRS3123 for C. Difficile Infections (CDI)
drugs.com - 05/Sep 05:09
BOULDER, Colo.--(BUSINESS WIRE)-- September 05, 2024 -- Crestone, Inc. (“Crestone”) today announced positive topline results from the Phase 2...
Nxera Pharma to get US$ 35 mn from Neurocrine for successful completion of phase 2 trial with NBI─1117568 in adults with schizophrenia
pharmabiz.com - 03/Sep 00:00
Nxera Pharma Co., Ltd.(formerly known as Sosei Group or Sosei Heptares), announces that it will receive a US$ 35 million payment from Neurocrine...
First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma
drugs.com - 09/Sep 20:09
HOUSTON, Sept. 9, 2024. Moleculin Biotech, Inc., ("Moleculin" or the "Company), a Phase 3 clinical-stage pharmaceutical company with a broad portfolio...
Clinical Pharmacist – Operations Manager at IQVIA
jobwebkenya.com - 11/Sep 19:05
IQVIA, formerly Quintiles and IMS Health, Inc.,is an American multinational company serving the combined industries of health information technology...
Bharat Biotech, Alopexx Inc of US to co-develop, commercialise anti-microbial vax AV0328
times of india - 11/Sep 09:13
Bharat Biotech has teamed up with Alopexx Inc to co-develop and market the broad-spectrum antimicrobial vaccine AV0328 in India and other low-income...
Bharat Biotech, Alopexx Inc of US to co-develop, commercialise anti-microbial vax AV0328
times of india - 11/Sep 09:13
Bharat Biotech has teamed up with Alopexx Inc to co-develop and market the broad-spectrum antimicrobial vaccine AV0328 in India and other low-income...
Les derniers communiqués
-
Aucun élément